Dalbavancin is a second-generation lipoglycopeptide antibiotic with a very long half-life enabling weekly or biweekly dosing, used for acute bacterial skin and skin-structure infections caused by Gram-positive organisms including MRSA. Simson Pharma's Dalbavancin reference standard and impurities support QC for this long-acting injectable antibiotic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dalbavancin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.